Introduction
Despite increasing access to effective antiviral therapies, HCV infection remains an important epidemiological issue worldwide, with about 3 to 4 million cases reported each year. 1 Approximately 75-85% of HCV-infected patients develop chronic HCV infection, 20% of whom progress to cirrhosis. 2 It is well known that oxidative stress plays a significant role in HCV pathogenesis. 3, 4 Hepatitis C virus core proteins induce the mitochondrial production of reactive oxygen species (ROS), leading to the peroxidation of membrane lipids. In response to this oxidative stress, adaptive antioxidant defenses such as antioxidant enzymes are upregulated in the liver. The main regulator of this self-protective antioxidant mechanism is nuclear factor erythroid 2-related factor-2 (Nrf2), encoded by the NFE2L2 gene, which activates the expression of antioxidant proteins such as glutathione perioxidase, NAD(P)H-quinone oxidoreductase-1, superoxide dismutase, catalase, glutathione S-transferases, glutamate-cysteine ligase, heme oxygenase-1, thioredoxin reductase-1, and augmenter of liver regeneration.
5 NQO1(NAD(P)H:quinone oxidoreductase-1) is a cytosolic flavoprotein encoded by the gene NQO1 that inhibits oxidative stress by the detoxification of superoxide anions and the regeneration of reduced forms of protective endogenous antioxidant compounds. 6 Augmenter of liver regeneration (ALR) is encoded by the growth factor erv1-like (GFER) gene and is responsible for liver regeneration through the upregulation of the mitogen-activated protein kinase pathway, as well as interleukin-6 (IL-6) and tumor necrosis factor-α. 7 The aim of the present study is to assess the hepatic expression of the antioxidant genes GFER and NQO1 and the regulatory gene NFE2L2 in liver biopsy specimens obtained from patients with chronic HCV in relation to selected clinical parameters and histological factors, and to determine whether GFER and NQO1 expression is dependent on NFE2L2.
Material and methods
The study included 42 adult patients with chronic HCV. Inclusion criteria were as follows: 1. The presence of positive serum anti-HCV antibodies and detectable HCV viremia lasting more than 6 months; 2. HCV genotype 1. 
mRNA expression
Homo sapiens-specific TaqManGene Expression Assay (Applied Biosystems Inc., Foster City, USA) for GFER, NQO1 and NFE2L2 mRNA was used for gene expression assays. cDNA generation was performed using 250 ng of total RNA with High Capacity cDNA Reverse Transcription Kits according to the manufacturer's protocols (Applied Biosystems). Expression levels of mRNA were determined using beta-actin (ACTB) as an endogenous control.
Real-time polymerase chain reaction analysis
TaqMan PCR assays were determined using Sequence Detection System v. 2.0 software (Thermo Fisher Scientific). Fold induction values were measured according to 2ΔΔCt, where ΔCt defines the differences in cycle threshold numbers between the target gene and endogenous control, and ΔΔCt defines the relative change in these differences between study and control groups.
Statistical analysis
The Mann-Whitney test was used to determine differences between the examined groups. Correlations between the hepatic expression of antioxidant genes GFER and NQO1 and the regulatory gene NFL2L2 were assessed with Spearman's rank correlation coefficient. Values of p ≤ 0.05 were considered to be statistically significant.
Results

Study group
The study group consisted of 42 patients with chronic HCV infection: 11 women and 31 men. The median age of patients was 32 years (LQ 21 years-UQ 49 years). The median plasma HCV viral load was 4,145,000 IU/mL (LQ 388,000 IU/mL-UQ 6,890,000 IU/mL). The characteristics of the patients are presented in Table 1 .
Hepatic expression of GFER, NQO1, NFE2L2, and HCV viral load
The study group was divided into 2 subgroups: one with HCV-RNA > 600,000 IU/mL and the other with HCV-RNA < 600,000 IU/mL. No significant difference in the hepatic expression of GFER, NQO1 and NFE2L2 was observed between the 2 groups ( Table 2) .
Hepatic expression of GFER, NQO1 and NFE2L2 in the context of inflammation, steatosis and fibrosis
Advanced fibrosis (S ≥2) was detected in 34 patients. No significant difference in the hepatic expression of GFER or NQO1 was observed in relation to the progression of liver fibrosis. However, the hepatic expression of NFE2L2 was significantly lower in patients with advanced liver fibrosis (p = 0.05) ( Table 3) . No relationships were found between the hepatic expression of GFER, NQO1 or NFE2L2 and the grade of inflammatory activity (Table 4) . Again, the hepatic expression of GFER, NQO1 or NFE2L2 was not associated with the presence of liver steatosis (Table 5 ). However, older age was reported in patients with the higher grade of liver inflammation (p < 0.0001) and HCV-RNA > 600,000 IU/mL (p = 0.03) ( Tables 2,4) .
Correlations between hepatic expression of GFER, NQO1 and NFE2L2
A significant positive correlation was found between the hepatic expression of NFE2L2 and NQO1 in chronic HCV patients (p < 0.0001). However, the hepatic expression of NFE2L2 was not associated with GEFR (Table 6 ). 
Discussion
Polymerase chain reaction proteins induce the production of more ROS in the liver than other hepatitis viruses. [8] [9] [10] As excessive production of ROS can result in hepatocyte damage, an adequate antioxidant response is extremely important. The transcription factor Nrf2 plays a central role in stimulating the expression of various antioxidant-associated genes. Numerous reports describe that the antioxidant response is disturbed in subjects with HCV infection. 11, 12 It is possible that HCV can directly affect regulatory genes responsible for the antioxidant response, such as NFE2L2. Carvajal-Yepes et al. indicate that HCV prevents the entry of Nrf2 in the nucleus by the delocalization of sMaf proteins, thereby inhibiting the induction of Nrf2/AREregulated genes. 13 Reduced levels of glutathione and other antioxidants have been reported in liver biopsies in chronic HCV. 14, 15 Interestingly, these results correspond to those of an in vitro study conducted by Wen at al., which indicates the decreased induction of HMOX-1 in hepatocyte cell lines expressing the HCV core protein in response to oxidative stress. 12 Conversely, Inanov et al. demonstrated that HCV proteins activate the Nrf2/ARE pathway in HCVcc infected Huh7.5 cells and induce the transcription of antioxidant genes. 9 Our results confirm the involvement of Nrf2 in the regulation of the antioxidant defense system, in that a positive correlation was observed between NFE2L2 and NQO1 expression.
Interestingly, the literature presents several contradicting opinions on the role of antioxidant enzymes in HCV replication. Zhu et al. demonstrated that heme oxygenase-1 overexpression is associated with decreased HCV replication in vitro. 16 In contrast, Ghaziani et al. found the heme oxygenase-1 gene to be upregulated in Huh-7 cells expressing HCV proteins. 17 It is still not clear whether antioxidant enzymes directly affect HCV replication in vivo; however, our present findings indicate that the hepatic expression of GFER, NQO1 and NFE2L2 was not related to HCV viremia.
A number of studies have examined the role of the antioxidant response in hepatocyte injury. 18, 19 In a study conducted by Kumar et al., the decreased hepatic expression of ALR was found in alcohol-induced fibrosis in mice model. 19 Conversely, Cheng et al. reported the expression of NQO1 to be increased in alcoholic cirrhosis. 20 Our present findings did not indicate any association between hepatic expression of GFER and NQO1 with the progression of liver inflammation and fibrosis in chronic HCV. However, higher hepatic expression of NFE2L2 was observed in patients with a lower stage of fibrosis.
Interestingly, Nrf2 activation directly inhibits the functioning of TGF-β1 (transforming growth factor-β1) and subsequently suppresses the collagen-producing hepatic stellate cells in a liver fibrosis mouse model. 21 These findings are in accordance with Jiang et al., who reported stronger Nrf2 staining in HCV infected Huh 7.5.1 hepatocytes and in liver biopsy specimens obtained from chronic HCV patients with a low grade of inflammation and fibrosis. 22 Moreover, experimental studies show that the decreased expression of ALR and Nfr2 can result in liver steatosis by lowering the activity of several enzymes important for fatty acid β-oxidation and the promoting factors that regulate adipocyte differentiation and lipogenesis. 19, 23, 24 However, our findings do not confirm the influence of NFE2L2 and GFER on the presence of liver steatosis in HCV infection in vivo. The pathogenesis of liver steatosis in HCV infection is complex. Not only the host but also viral mechanisms likely contribute to the development of hepatic steatosis in HCV infection. 25, 26 The limitation of this study is the lack of the assessment of oxidative stress markers in the liver. Therefore, further studies are needed to precisely clarify the simultaneous role of the oxidative stress and antioxidant response in pathogenesis of chronic HCV. In conclusion, the hepatic expression of NFE2L2 is associated with NQO1 and low stage of fibrosis in patients infected with HCV. However, the study subgroup with mild fibrosis was limited to 8 patients.
